Drug Status Key

  • Preferred
  • On Formulary
  • Specialist Initiation
  • Shared Care
  • Hospital Only
  • Under Review
  • New on System

1.9.4 Pancreatin

The CSM has advised of data associating the high-strength pancreatin preparations with the development of large bowel strictures in children with cystic fibrosis aged between 2 and 13 years and recommended that the total dose of pancreatic enzyme supplements used in patients with cystic fibrosis should not usually exceed 10,000 units of lipase per kg body-weight daily.
It is important to ensure adequate hydration at all times in patients receiving higher strength pancreatin preparations.

Additional NICE Guidance
NG49 (Jul 2016): Non-alcoholic fatty liver disease (NAFLD): assessment and management
NG50 (Jul 2016): Cirrhosis in over 16s: assessment and management
CG141 (Aug 2016): Acute upper gastrointestinal bleeding in over 16s: management

Please note, sample information has been entered into Chapters 1 and 2 only and although fairly clinically accurate, it is not guaranteed. The information was entered during April and May 2017 and drugs will have subsequently been randomly added during telephone demonstrations.

Show All

Pack Price
100 capsule
Pack Price
100 capsule
Pack Price
100 capsule
200 capsule
Pack Price
300 capsule £53.20
Pack Price
300 tablet £48.11